We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA授予Langlara与Lantus可互换的生物类似药地位。了解这将如何改变美国胰岛素市场并扩大患者获得治疗的机会。
FDA批准了来自中国东阳光药的可互换生物类似药甘精胰岛素Langlara。了解这将如何改变美国市场及患者价格。内附详细分析。